Sales of STELFONTA are disappointing and well below initial forecasts, they have underestimated how difficult it is to get this drug into the vet market.
But there are many positives for Qbiotics with the active trials that they have running.
Cash in bank is healthy, $54M with tax rebate, with an average yearly spend of $18M/yr, gives us at least 2 years to sign up a partner.. Depending on trial results, i am hoping that we will list on the ASX by October/November 2024.
